Long-term outcome of liver transplantation for autoimmune hepatitis

Clinical Transplantation

Volumn 18, Issue 1, 2004, Pages 62-69

  Vogel, Arndt ^a   Heinrich, Eyk ^a   Bahr, Matthias J ^a   Rifai, Kinan ^a   Flemming, Peer ^a   Melter, Michael ^a   Klempnauer, Juergen ^a   Nashan, Björn ^a   Manns, Michael P ^a   Strassburg, Christian P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute rejection; Autoimmune hepatitis; Liver kidney autosomal antibodies; Orthotopic liver transplantation; Recurrence; Soluble liver antigen autoantibodies

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CHILD; CHRONIC GRAFT REJECTION; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 1; GRAFT SURVIVAL; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER TRANSPLANTATION; LONG TERM CARE; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEROLOGY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WILSON DISEASE;

ADOLESCENT; ADULT; AUTOANTIBODIES; CASE-CONTROL STUDIES; FEMALE; GRAFT REJECTION; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 10744219677     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00117.x     Document Type: Article

References (41)

1. Manns MP, Krüger M. Genetics in liver diseases. Gastroenterology 1994: 106: 1676.
2. Gregorio GV, Portman B, Reid F et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997: 25: 541.
3. Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001: 120: 1502.
4. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991: 88: 1370.
5. Strassburg CP, Obermayer-Straub P, Alex B et al. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 1996: 111: 1576.
6. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987: 1: 292.
7. Wies I, Brunner S, Henninger J et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000: 355: 1510.
8. Neuberger J. Transplantation for autoimmune hepatitis. Semin Liver Dis 2002: 22: 379.
9. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999: 31: 929.
10. Demetris A, Adams D, Bellamy C et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000: 31: 792.
11. Sebagh M, Blakolmer K, Falissard B et al. Accuracy of bile duct changes for the diagnosis of chronic liver allograft rejection: reliability of the 1999 Banff schema. Hepatology 2002: 35: 117.
12. Manns MP, Bahr MJ. Recurrent autoimmune hepatitis after liver transplantation - when non-self becomes self. Hepatology 2000: 32: 868.
13. Strassburg CP, Alex B, Zindy F et al. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. J Hepatol 1996: 25: 859.
14. Volkmann M, Martin L, Baurle A et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis type 3. Hepatology 2001: 33: 591.
15. Goss JA, Shackleton CR, McDiarmid SV et al. Long-term results of pediatric liver transplantation: an analysis of 569 transplants. Ann Surg 1998: 228: 411.
16. Bahar RJ, Yanni GS, Martin MG et al. Orthotopic liver transplantation for autoimmune hepatitis and cryptogenic chronic hepatitis in children. Transplantation 2001: 72: 829.
17. Duclos-Vallee JC, Johanet C, Bach JF, Yamamoto AM. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J Hepatol 2000: 33: 163.
18. Cancado ELR, Porta G. Autoimmune hepatitis in South America. Dordrecht, Boston, London: Kluwer Academic Publishers, 2000.
19. Narumi S, Hakamada K, Sasaki M et al. Liver transplantation for autoimmune hepatitis: rejection and recurrence. Transplant Proc 1999: 31: 1955.
20. Neuberger J. Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl Surg 1999: 5: S30.
21. Reich DJ, Fiel I, Guarrera JV et al. Liver transplantation for autoimmune hepatitis. Hepatology 2000: 32: 693.
22. Wright HL, Bou-Abboud CF, Hassanenstein T et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 1992: 53: 136.
23. Farges O, Saliba F, Farhamant et al. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins. Hepatology 1996: 23: 240.
24. Milkiewicz P, Gunson B, Saksena S, Hathaway M, Hubscher SG, Elias E. Increased incidence of chronic rejection in adult patients transplanted for autoimmune hepatitis: assessment of risk factors. Transplantation 2000: 70: 477.
25. Jain A, Kashyap R, Marsh W, Rohal S, Khanna A, Fung JJ. Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus, Transplantation 2001: 71: 1102.
26. Götz G, Neuhaus R, Bechstein WO et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplant Proc 1999: 31: 430.
27. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999: 68: 253.
28. Prados E, Cuervas-Mons V, De La Mata M et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998: 66: 1645.
29. Ratziu V, Samuel D, Sebagh M et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999: 30: 131.
30. Gonzalez-Koch A, Czaja AJ, Carpenter HA et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001: 7: 302.
31. Dmitrewski J, Hubscher SG, Mayer AD, Neuberger JM. Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression. J Hepatol 1996: 24: 253.
32. Strassburg CP, Manns MP. Autoimmune hepatitis versus viral hepatitis C. Liver 1995: 15: 225.
33. Strassburg CP, Obermayer-Straub P, Manns MP. Autoimmunity in liver diseases. Clin Rev Allergy Immunol 2000: 18: 127.
34. Dubel L, Farges O, Courvalin JC, Sebagh M, Johanet C. Persistence of gp210 and multiple nuclear dots antibodies does not correlate with recurrence of primary biliary cirrhosis 6 years after liver transplantation. J Hepatol 1998: 28: 169.
35. Mattalia A, Luttig B, Rosina F et al. Persistence of autoantibodies against recombinant mitochondrial and nuclear pore proteins after orthotopic liver transplantation for primary biliary cirrhosis. J Autoimmun 1997: 10: 491.
36. Ahmed M, Mutimer D, Hathaway M, Hubscher S, McMaster P, Elias E. Liver transplantation for autoimmune hepatitis: a 12-year experience. Transplant Proc 1997: 29: 496.
37. Gouw AS, Haagsma EB, Manns M, Klompmaker IJ, Sloo MJ, Gerber MA. Is there recurrence of primary biliary cirrhosis after liver transplantation? A clinicopathologic study in long-term survivors. J Hepatol 1994: 20: 500.
38. Luettig B, Boeker KH, Schoessler W et al. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. J Hepatol 1998: 28: 824.
39. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002: 97: 413.
40. Ma Y, Okamoto M, Thomas MG et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002: 35: 658.
41. Gelpi CSE, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci USA 1992: 89: 9739.